幼年特发性关节炎治疗现状与展望  

Current status and prospects of the treatment of juvenile idiopathic arthritis

作　　者：杨思睿[1] 郭丽双[1] 刘金香[1] 刘聪聪[1] Yang Sirui;Guo Lishuang;Liu Jinxiang;Liu Congcong(Division of Rheumatology,Immunology and Allergy in the Department of Pediatrics,the First Hospital of Jilin University,Changchun 130021,China)

机构地区：[1]吉林大学第一医院儿童风湿免疫过敏科,长春130021

出　　处：《中华实用儿科临床杂志》2022年第1期6-12,共7页Chinese Journal of Applied Clinical Pediatrics

摘　　要：幼年特发性关节炎(JIA)是一组具有遗传异质性、病因不明、以慢性关节滑膜炎症为主要特征的儿童时期常见的结缔组织病,目前尚无法治愈,主要治疗目标是达到临床缓解。治疗JIA的药物目前主要包括非甾体类抗炎药、糖皮质激素、改变病情抗风湿药及生物制剂。现总结近年对JIA治疗的认识及相关临床研究的进展,并对未来药物的研发方向及治疗理念作一展望。Juvenile idiopathic arthritis(JIA)is a genetically heterogeneous group of connective tissue diseases that are commonly characterized by chronic joint synovial inflammation with unknown etiology in childhood.It is cu-rrently incurable and the main therapeutic goal is to achieve clinical remission.The drugs currently used to treat JIA mainly include non-steroid anti-inflammatory drugs,glucocorticoid,disease modifying antirheumatic drugs,and biological agents.In this article,recent advances in the understanding of JIA treatment and related clinical research were reviewed,in an attempt to provide prospects for the future direction of drug development and treatment concepts.

关 键 词：特发性关节炎 幼年 治疗 现状 展望 

分 类 号：R725.9[医药卫生—儿科]